Bmi-1 siRNA inhibited ovarian cancer cell line growth and decreased telomerase activity

British Journal of Biomedical Science

Volumn 69, Issue 2, 2012, Pages 62-66

  Xin, T ^a   Zhang, F B ^a   Sui, GuangJie ^a   Jin, X M ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Cell proliferation; Ovarian neoplasms; Telomerase; Tumorigenicity tests

Indexed keywords

BMI1 PROTEIN; MESSENGER RNA; SMALL INTERFERING RNA; TELOMERASE;

APOPTOSIS; ARTICLE; CANCER GROWTH; CELL IMMORTALIZATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; WESTERN BLOTTING;

EID: 84865187623     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: 10.1080/09674845.2012.12002438     Document Type: Article

References (25)

1. Breuer RHJ, Snijders PJF, Smit EF et al. Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis. Neoplasia 2004; 6 (6): 736-43. (Pubitemid 40041491)
2. Orlando V. Polycomb, epigenomes, and control of cell identity. Cell 2003; 112 (5): 599-606. (Pubitemid 36331773)
3. Park I, Qian D, Kiel M et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 2003; 423 (6937): 302-5. (Pubitemid 40852701)
4. Dimri GP, Martinez JL, Jacobs JJL et al. The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res 2002; 62 (16): 4736-45.
5. Silva J, García JM, Peña C et al. Implication of polycomb members Bmi-1, Mel-18, and Hpc-2 in the regulation of p16INK4a, p14ARF, h-TERT, and c-Myc expression in primary breast carcinomas. Clin Cancer Res 2006; 12 (23): 6929-36. (Pubitemid 44974485)
6. Guo BH, Feng Y, Zhang R et al. Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer. Mol Cancer 2011; 10 (1): 10.
7. Min L, Dong-Xiang S, Xiao-Tong G, Ting G, Xiao-Dong C. Clinicopathological and prognostic significance of Bmi 1 expression in human cervical cancer. Acta Obstet Gynecol Scand 2011; 90 (7): 737-45.
8. Zhang F, Sui L, Xin T. Correlations of BMI-1 expression and telomerase activity in ovarian cancer tissues. Exp Oncol 2008; 30 (1): 70-4. (Pubitemid 351518108)
9. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005; 115 (6): 1503-21. (Pubitemid 40814659)
10. Qin ZK, Yang JA, Ye Y et al. Expression of Bmi-1 is a prognostic marker in bladder cancer. BMC Cancer 2009; 9 (1): 61.
11. Chen YC, Chang CJ, Hsu HS et al. Inhibition of tumorigenicity and enhancement of radiochemosensitivity in head and neck squamous cell cancer-derived ALDH1-positive cells by knockdown of Bmi-1. Oral Oncol 2010; 46 (3): 158-65.
12. Song LB, Zeng MS, Liao WT et al. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res 2006; 66 (12): 6225-32.
13. Zhang XW, Sheng YP, Li Q et al. BMI1 and Mel-18 oppositely regulate carcinogenesis and progression of gastric cancer. Mol Cancer 2010; 9 (1): 40.
14. Song W, Tao K, Li H et al. Bmi-1 is related to proliferation, survival and poor prognosis in pancreatic cancer. Cancer Sci 2010; 101 (7): 1754-60.
15. Tahara H, Yasui W, Tahara E et al. Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections. Oncogene 1999; 18 (8): 1561-7. (Pubitemid 29108056)
16. Kim JH, Yoon SY, Kim CN et al. The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett 2004; 203 (2): 217-24. (Pubitemid 38058689)
17. Fujiwara T. Targeted oncolytic adenovirus for human cancer therapy: gene-based therapies for cancer. In: Roth JA ed. Gene-based therapies for cancer. New York: Springer, 2010: 79-93.
18. Liu L, Andrews L, Tollefsbol T. Loss of the human polycomb group protein BMI1 promotes cancer-specific cell death. Oncogene 2006; 25 (31): 4370-5. (Pubitemid 44100507)
19. Kim NW, Wu F. Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP). Nucleic Acids Res 1997; 25 (13): 2595-7. (Pubitemid 27298154)
20. Bhattacharya R, Kwon J, Ali B et al. Role of hedgehog signaling in ovarian cancer. Clin Cancer Res 2008; 14 (23): 7659-66.
21. Yang G-F, He W-P, Cai M-Y et al. Intensive expression of Bmi-1 is a new independent predictor of poor outcome in patients with ovarian carcinoma. BMC Cancer 2010; 10 (1): 133.
22. Lu YW, Li J, Guo WJ. Expression and clinicopathological significance of Mel-18 and Bmi-1 mRNA in gastric carcinoma. J Exp Clin Cancer Res 2010; 29 (1): 1-7.
23. Saito M, Handa K, Kiyono T et al. Immortalization of cementoblast progenitor cells with Bmi-1 and TERT. J Bone Miner Res 2005; 20 (1): 50-7. (Pubitemid 41716218)
24. Greenberg RA, O'Hagan RC, Deng H et al. Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation. Oncogene 1999; 18 (5): 1219-26. (Pubitemid 29085995)
25. Ball AJ, Levine F. Telomere-independent cellular senescence in human fetal cardiomyocytes. Aging Cell 2005; 4 (1): 21-30. (Pubitemid 41583136)